Credit: Vertex. A new oral granule formulation has been approved and is supplied in morning and evening unit-dose packets. The approval was based on data from a 24-week open-label, two-part phase 3 ...

The cost of a popular Vertex Pharmaceuticals therapy could be contributing to cystic fibrosis (CF) treatment disparities around the world, researchers argued in a recent paper. Just 12% of some ...

Getting your Trinity Audio player ready... Colorado’s new prescription drug review board decided in a first-in-the-nation vote that a medication costing more than $200,000 a year doesn’t qualify as ...

I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic ...

Over the past three decades, meaningful progress has been made in the research and understanding of cystic fibrosis (CF). 1 ...

The expanded approval was based on clinical and/or in vitro data demonstrating responsiveness across 564 variants for Alyftrek and 521 variants for Trikafta. The label expansions were granted based on ...

The cystic fibrosis drug Trikafta helps roughly 90 percent of patients, while the other 10 percent are still waiting for their "miracle drug." (Randy Vazquez/Globe Staff) The cystic fibrosis drug ...

Vertex Pharmaceuticals Incorporated’s VRTX first-quarter 2026 results were decent as it beat estimates for earnings and sales ...

Cystic fibrosis (CF) patients and their families in England can rest a little easier this week, thanks to an extended long-term reimbursement deal inked by Vertex Pharmaceuticals and the country’s ...